M
Marie Will
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 4
Citations - 1308
Marie Will is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Receptor & Protein kinase B. The author has an hindex of 3, co-authored 4 publications receiving 1129 citations. Previous affiliations of Marie Will include Cornell University.
Papers
More filters
Journal ArticleDOI
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy,Yang Shen,Helen Won,Bradley Green,Rita A. Sakr,Marie Will,Zhiqiang Li,Kinisha Gala,Sean W. Fanning,Tari A. King,Clifford A. Hudis,Clifford A. Hudis,David Chen,Tetiana Taran,Gabriel N. Hortobagyi,Geoffrey L. Greene,Michael F. Berger,José Baselga,José Baselga,Sarat Chandarlapaty,Sarat Chandarlapaty +20 more
TL;DR: A comprehensive genetic analysis of two independent cohorts of metastatic ER-positive breast tumors and identified mutations in ESR1 affecting the ligand-binding domain (LBD) in 14 of 80 cases that implicate LBD-mutant forms of ER in mediating clinical resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.
Journal ArticleDOI
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.
Sarit Schwartz,John Wongvipat,Cath Trigwell,Urs Hancox,Brett S. Carver,Vanessa Rodrik-Outmezguine,Marie Will,Paige Yellen,Elisa de Stanchina,José Baselga,Howard I. Scher,Simon T. Barry,Charles L. Sawyers,Sarat Chandarlapaty,Sarat Chandarlapaty,Neal Rosen,Neal Rosen +16 more
TL;DR: In PTEN-deficient models of prostate cancer, this effective inhibition of PI3K causes marked activation of androgen receptor activity, and combined inhibition of both PI2K isoforms and androgen receptors results in major tumor regressions.
Journal ArticleDOI
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling
Marie Will,Alice Can Ran Qin,Weiyi Toy,Zhan Yao,Vanessa Rodrik-Outmezguine,Claudia Schneider,Xiaodong Huang,Prashant Monian,Xuejun Jiang,Elisa de Stanchina,José Baselga,Ningshu Liu,Sarat Chandarlapaty,Neal Rosen +13 more
TL;DR: It is concluded that PI3K is upstream of RAS and AKT and that pulsatile inhibition of both pathways is sufficient for effective antitumor activity.
Journal ArticleDOI
417 A Mechanistic Logic for Dual Targeting of HER2 and PI3K/AKT/mTOR Signaling in HER2 Amplified Breast Cancer
S Chandarlapaty,Vanessa S. Rodrik-Outmezguine,Maurizio Scaltriti,Rita A. Sakr,Marie Will,Dilip Giri,Clifford A. Hudis,J. Baselga,Tari A. King,Neal Rosen +9 more
TL;DR: This research highlights the need to understand more fully the role of “cell reprograming” in the development of solid tumourigenicity and its role in the immune response.